Aclaris Therapeutics, Inc. (ACRS) Cash Flow Statement

In the most recent quarters, OCF/NI ratios hovered near 0.9, suggesting that reported losses are largely cash-based, with minimal non-cash adjustments beyond stock-based compensation. The 2024Q4 anomaly, where OCF/NI dropped to 0.09, reflects a one-time impairment that did not consume cash, indicating that the underlying cash burn is more consistent than net income volatility suggests.

The quarterly FCF deficit has remained persistently negative, with the latest quarter's -$19.9M FCF representing a 12.2% negative margin on revenue of $1.6M. This indicates that the company's cash consumption is not abating, and the slight improvement from 2024Q4's -$44.7M is misleading due to that quarter's one-time impairment and elevated capex. The trajectory suggests that without a significant revenue inflection or cost reduction, the cash runway will be exhausted within a few quarters.

The negligible capital expenditure, with the highest quarter at $35.8M in 2024Q4 (likely a one-time asset acquisition), underscores that ACRS's cash burn is driven by operating expenses, particularly R&D, rather than capital investment. This suggests that the company's infrastructure is largely intangible, and any future growth would require increased spending on clinical trials rather than physical capacity.

The positive working capital adjustments in earlier quarters likely stemmed from favorable timing of payables or collections, providing a temporary cushion to cash burn. However, the recent negative changes, such as -$1.4M in 2026Q2, indicate that this source of liquidity is reversing, potentially reflecting tighter vendor terms or reduced accruals. This suggests that the company cannot rely on working capital management to offset its operational losses.

The absence of shareholder returns and M&A underscores that the company is in survival mode, conserving every dollar for R&D and general operations. The minimal buybacks, which were likely to offset dilution from employee stock plans, do not signal confidence in undervaluation. This capital deployment strategy is consistent with a company facing a liquidity crunch, where preserving cash is paramount.

The gap between net income and operating cash flow, totaling over $133M, is primarily attributable to the 2024Q4 impairment and stock-based compensation. This divergence suggests that while the company's cash burn is severe, the reported losses overstate the immediate cash drain, but the underlying trend is still unsustainable. Investors should monitor whether future impairments or non-cash items continue to mask the true cash consumption rate.